HRP20040370B1 - Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder - Google Patents
Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorderInfo
- Publication number
- HRP20040370B1 HRP20040370B1 HRP20040370AA HRP20040370A HRP20040370B1 HR P20040370 B1 HRP20040370 B1 HR P20040370B1 HR P20040370A A HRP20040370A A HR P20040370AA HR P20040370 A HRP20040370 A HR P20040370A HR P20040370 B1 HRP20040370 B1 HR P20040370B1
- Authority
- HR
- Croatia
- Prior art keywords
- estra
- benzodioxol
- dien
- propynyl
- hydroxy
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- DBLOJPKZEOYNBN-SQNIBIBYSA-N (8s,13s,14s)-13-methyl-2,6,7,8,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 DBLOJPKZEOYNBN-SQNIBIBYSA-N 0.000 abstract 1
- -1 1,3-benzodioxol-5-yl Chemical group 0.000 abstract 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204072 | 2001-10-26 | ||
| PCT/EP2002/011732 WO2003037354A1 (en) | 2001-10-26 | 2002-10-21 | USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20040370A2 HRP20040370A2 (en) | 2004-08-31 |
| HRP20040370B1 true HRP20040370B1 (en) | 2012-09-30 |
Family
ID=8181136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20040370AA HRP20040370B1 (en) | 2001-10-26 | 2004-04-26 | Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20040266863A1 (xx) |
| EP (2) | EP1652526B1 (xx) |
| JP (1) | JP4647909B2 (xx) |
| KR (1) | KR20050038580A (xx) |
| CN (1) | CN100531738C (xx) |
| AT (2) | ATE420649T1 (xx) |
| AU (1) | AU2002348996B2 (xx) |
| BR (1) | BR0213466A (xx) |
| CA (1) | CA2463446C (xx) |
| CY (1) | CY1110173T1 (xx) |
| DE (2) | DE60209248D1 (xx) |
| DK (1) | DK1652526T3 (xx) |
| EC (1) | ECSP045080A (xx) |
| ES (1) | ES2319563T3 (xx) |
| HK (1) | HK1087357A1 (xx) |
| HR (1) | HRP20040370B1 (xx) |
| HU (1) | HUP0500070A3 (xx) |
| IL (2) | IL161248A0 (xx) |
| IS (1) | IS2702B (xx) |
| MX (1) | MXPA04003781A (xx) |
| NO (1) | NO332978B1 (xx) |
| NZ (1) | NZ532429A (xx) |
| PL (1) | PL206687B1 (xx) |
| PT (1) | PT1652526E (xx) |
| RU (1) | RU2302245C2 (xx) |
| WO (1) | WO2003037354A1 (xx) |
| ZA (1) | ZA200403088B (xx) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050080061A1 (en) * | 2003-07-23 | 2005-04-14 | Corcept Therapeutics, Inc. | Antiglucocorticoid therapy for the prevention of neurological damage in premature infants |
| AU2011236053B2 (en) * | 2004-11-19 | 2014-06-26 | Merck Sharpe & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
| CA2585317C (en) * | 2004-11-19 | 2015-02-24 | N.V. Organon | Drug combination for the treatment of depression and related disorders comprising a selective serotonin reuptake inhibitor |
| EP2012796A4 (en) * | 2006-05-02 | 2010-08-11 | Corcept Therapeutics Inc | USE OF GLUCOCORTICOID TYPE II RECEPTOR ANTAGONISTS TO TREAT PATIENT DEPRESSION WITH IL-2 |
| EP2671086B1 (en) * | 2011-02-03 | 2018-04-25 | Pop Test Oncology LLC | System and method for diagnosis and treatment |
| US20120263660A1 (en) * | 2011-04-18 | 2012-10-18 | Pop Test Cortisol Llc | Hair Loss Treatment |
| US8986677B2 (en) * | 2012-07-30 | 2015-03-24 | Pop Test Cortisol Llc | Therapeutic compositions and methods |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| EP0763541A1 (en) * | 1995-08-17 | 1997-03-19 | Akzo Nobel N.V. | 11-(Substituted phenyl)-estra-4,9-diene derivatives |
| WO1999017779A1 (en) * | 1997-10-06 | 1999-04-15 | The Board Of Trustees Of Leland Stanford Jr. University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| WO2002076390A2 (en) * | 2001-03-23 | 2002-10-03 | Corcept Therapeutics, Inc. | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19727772A1 (de) * | 1997-06-30 | 1999-01-28 | Forschungszentrum Juelich Gmbh | Magnetflußsensor mit ringförmiger Sonde |
| NZ531477A (en) * | 2001-08-31 | 2006-10-27 | Corcept Therapeutics Inc | Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome |
-
2002
- 2002-10-21 DK DK06101005T patent/DK1652526T3/da active
- 2002-10-21 RU RU2004116082/15A patent/RU2302245C2/ru not_active IP Right Cessation
- 2002-10-21 EP EP06101005A patent/EP1652526B1/en not_active Expired - Lifetime
- 2002-10-21 PL PL369261A patent/PL206687B1/pl not_active IP Right Cessation
- 2002-10-21 EP EP02781273A patent/EP1441739B1/en not_active Withdrawn - After Issue
- 2002-10-21 AT AT06101005T patent/ATE420649T1/de active
- 2002-10-21 MX MXPA04003781A patent/MXPA04003781A/es active IP Right Grant
- 2002-10-21 PT PT06101005T patent/PT1652526E/pt unknown
- 2002-10-21 NZ NZ532429A patent/NZ532429A/en not_active IP Right Cessation
- 2002-10-21 ES ES06101005T patent/ES2319563T3/es not_active Expired - Lifetime
- 2002-10-21 KR KR1020047006050A patent/KR20050038580A/ko not_active Application Discontinuation
- 2002-10-21 US US10/493,981 patent/US20040266863A1/en not_active Abandoned
- 2002-10-21 CN CNB028210417A patent/CN100531738C/zh not_active Expired - Fee Related
- 2002-10-21 JP JP2003539697A patent/JP4647909B2/ja not_active Expired - Fee Related
- 2002-10-21 HU HU0500070A patent/HUP0500070A3/hu unknown
- 2002-10-21 CA CA2463446A patent/CA2463446C/en not_active Expired - Fee Related
- 2002-10-21 IL IL16124802A patent/IL161248A0/xx unknown
- 2002-10-21 BR BR0213466-7A patent/BR0213466A/pt not_active IP Right Cessation
- 2002-10-21 DE DE60209248T patent/DE60209248D1/de not_active Expired - Lifetime
- 2002-10-21 DE DE60230936T patent/DE60230936D1/de not_active Expired - Lifetime
- 2002-10-21 AU AU2002348996A patent/AU2002348996B2/en not_active Ceased
- 2002-10-21 WO PCT/EP2002/011732 patent/WO2003037354A1/en not_active Application Discontinuation
- 2002-10-21 AT AT02781273T patent/ATE317700T1/de active
-
2004
- 2004-03-31 IS IS7204A patent/IS2702B/is unknown
- 2004-04-01 IL IL161248A patent/IL161248A/en not_active IP Right Cessation
- 2004-04-22 ZA ZA200403088A patent/ZA200403088B/en unknown
- 2004-04-23 NO NO20041651A patent/NO332978B1/no not_active IP Right Cessation
- 2004-04-23 EC EC2004005080A patent/ECSP045080A/es unknown
- 2004-04-26 HR HRP20040370AA patent/HRP20040370B1/xx not_active IP Right Cessation
-
2006
- 2006-08-29 HK HK06109619.6A patent/HK1087357A1/xx not_active IP Right Cessation
-
2009
- 2009-02-02 CY CY20091100116T patent/CY1110173T1/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4814333A (en) * | 1987-07-28 | 1989-03-21 | The Trustees Of Dartmouth College | Method for treatment of hypercortisolemic, depressed patients |
| EP0763541A1 (en) * | 1995-08-17 | 1997-03-19 | Akzo Nobel N.V. | 11-(Substituted phenyl)-estra-4,9-diene derivatives |
| WO1999017779A1 (en) * | 1997-10-06 | 1999-04-15 | The Board Of Trustees Of Leland Stanford Jr. University | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| WO2002076390A2 (en) * | 2001-03-23 | 2002-10-03 | Corcept Therapeutics, Inc. | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| WO2002096433A1 (en) * | 2001-05-04 | 2002-12-05 | Corcept Therapeutics, Inc. | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600964A1 (ru) | Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина | |
| EP1311247A4 (en) | ORAL PHARMACEUTICAL FORMULA FOR THE PULSATIVE ADMINISTRATION OF AN ANTIARRHYTHMIC ACTIVE SUBSTANCE | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| MY127290A (en) | New use of flibanserin | |
| BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
| HK1068606A1 (en) | Novel aminobenzoephenones | |
| HUP0301460A2 (hu) | Antiprogresztinek használata hormonfüggő betegségek megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállításához | |
| HRP20040370B1 (en) | Use of (11c, 17c)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder | |
| NO20101070L (no) | Fremgangsmate til dosering av et medikament, samt doseringsform | |
| WO2002011694A3 (en) | COMPOSITIONS AND DOSAGE FORMS FOR APPLICATION IN ORAL CAVITY IN THE TREATMENT OF MYCOSIS | |
| PT1656131E (pt) | Utilização de betaína para tratar claudicação intermitente | |
| GB0010683D0 (en) | Cancer therapy | |
| AU3885799A (en) | Antidepressant therapy | |
| WO2002074315A8 (de) | Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie | |
| EA200701389A1 (ru) | Твёрдая пероральная лекарственная форма для контрацепции | |
| JP2005521637A5 (xx) | ||
| NO20072687L (no) | Farmasoytisk prevensjonspreparat | |
| FR2839450B1 (fr) | Preparation medicamenteuse notamment pour le traitement des hernies discales | |
| RS50350B (sr) | Upotreba 11beta-(4-acetilfenil)-17beta-hidroksi-17alfa-(1,1,2,2,2-pentafluoretil)estra-4,9-dien-3-ona za pripremanje medikamenta za lečenje kancera dojke, jajnika, endometrijuma, mijeloma i meningioma | |
| IL162391A (en) | Use of darifenacin in the manufacture of medicaments for reducing urgency in dry overactive bladder patients | |
| CA2403674A1 (en) | The use of t3 for treating congestive heart failure | |
| HRP20020666B1 (en) | Drospirenone for hormone replacement therapy | |
| DK1937274T3 (da) | Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception | |
| EP1759734A3 (en) | Aromatase inhibition to enhance assisted reproduction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PPPP | Transfer of rights |
Owner name: N.V. ORGANON, NL |
|
| PPPP | Transfer of rights |
Owner name: POP TEST CORTISOL LLC, US |
|
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20121011 Year of fee payment: 11 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20131021 |